RxDoctor Payments Data

Ajeet Dhingra, MD

Ophthalmology · Decatur, GANPI 1184625907

Payments from drug & device makers

$8,462in general payments, 2019–2025

Across 252 payments — averaging $33.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Sun Pharmaceutical Industries Inc.$1K
  • Notal Vision, Inc.$864
  • Alcon$862
  • Glaukos Corporation$731
  • Johnson & Johnson Surgical Vision, Inc.$574
  • plus $3K from 30 others

What the payments were for

  • Food & beverage$8,443100%
  • Gifts$190%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,462 in reported general payments places this provider in the 75th percentile of 481 ophthalmology providers in Georgia.

See all ophthalmology providers in Georgia

Medicare billing

Part B allowed, 2024
$208,888
Medicare patients
639
Services billed
2,003

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost195$99,036
RestasisCyclosporine47$63,265
RocklatanNetarsudil Mesylat/Latanoprost61$47,478
VyzultaLatanoprostene Bunod74$36,485
SimbrinzaBrinzolamide/Brimonidine Tart117$36,347
Alphagan PBrimonidine Tartrate63$27,994
CequaCyclosporine12$13,824
TyrvayaVarenicline Tartrate20$12,816
XiidraLifitegrast12$12,661
CombiganBrimonidine Tartrate/Timolol24$10,325
Brimonidine Tartrate169$8,929
Cyclosporine12$7,520
Travoprost45$6,989
Latanoprost434$5,374
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol30$2,703

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Alphagan P, Combigan$1,114$200,619329 claims
Bausch & Lomb Americas Inc.Vyzulta, Xiidra$158$49,14586 claims
Aerie Pharmaceuticals, Inc.Rocklatan$139$47,47861 claims
AlconSimbrinza$862$36,347117 claims
Sun Pharmaceutical Industries Inc.Cequa$1,013$13,82412 claims
Oyster Point Pharma, Inc.Tyrvaya$272$12,81620 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$31$1,17511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 481 ophthalmology providers in Georgia.

Other ophthalmology in Decatur

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →